Acumen Pharmaceuticals (ABOS)
NASDAQ:ABOS
Want to see ABOS full AI Analyst Report?
ABOS Stock Chart & Stats
$2.82
-$0.08(-4.37%)
At close: 4:00 PM EST
$2.82
-$0.08(-4.37%)
Day’s Range― - ―
52-Week Range$0.96 - $3.60
Previous CloseN/A
Volume101.31K
Average Volume (3M)415.59K
Market Cap
$179.12M
Enterprise Value$129.97M
Total Cash (Recent Filing)$116.86M
Total Debt (Recent Filing)$31.31M
Price to Earnings (P/E)―
Beta2.18
Next Earnings
May 19, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.02
Shares Outstanding72,227,580
10 Day Avg. Volume506,634
30 Day Avg. Volume415,590
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)1.81
Price to Sales (P/S)0.00
P/FCF Ratio-1.11
Enterprise Value/Market Cap0.73
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-2.89K
Enterprise Value/Ebitda-1.10
Forecast
1Y Price Target
$8.00Price Target Upside183.69% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-1.65
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Capital And Program FundingA recent capital infusion designated for the shuttle program eases cash constraints and supports continued advancement of clinical development.
Preclinical Brain DeliveryNon-human primate data demonstrating substantially higher brain penetration for enhanced delivery candidates with no anemia observations imply a potential safety and efficacy advantage over existing approaches.
Regulatory And Dosing ConvenienceRegulatory acceptance of a subcutaneous induction filing for an Alzheimer's antibody indicates growing support for more convenient dosing, which could broaden patient access and boost demand for similar therapies.
Bears Say
Clinical Benefit UncertaintyA subcutaneous filing that relies on demonstrating plaque removal rather than direct cognitive benefit raises concern that measurable clinical improvement may be delayed if high initial drug exposure is needed to saturate plaque.
Program Maturity And Commercial TimelineNext-generation antibody programs remain early stage and are unlikely to contribute to the company's first marketed product, limiting near-term commercial impact.
Safety Profile And Brain Swelling RiskThe subcutaneous formulation does not appear to reduce the main brain swelling risk compared with intravenous dosing, which could constrain any improvement in the overall risk–benefit profile.
Acumen Pharmaceuticals News
ABOS FAQ
What was Acumen Pharmaceuticals’s price range in the past 12 months?
Acumen Pharmaceuticals lowest stock price was $0.96 and its highest was $3.60 in the past 12 months.
What is Acumen Pharmaceuticals’s market cap?
Acumen Pharmaceuticals’s market cap is $179.12M.
When is Acumen Pharmaceuticals’s upcoming earnings report date?
Acumen Pharmaceuticals’s upcoming earnings report date is May 19, 2026 which is in 13 days.
How were Acumen Pharmaceuticals’s earnings last quarter?
Acumen Pharmaceuticals released its earnings results on Mar 26, 2026. The company reported -$0.4 earnings per share for the quarter, beating the consensus estimate of -$0.453 by $0.053.
Is Acumen Pharmaceuticals overvalued?
According to Wall Street analysts Acumen Pharmaceuticals’s price is currently Undervalued.
Does Acumen Pharmaceuticals pay dividends?
Acumen Pharmaceuticals does not currently pay dividends.
What is Acumen Pharmaceuticals’s EPS estimate?
Acumen Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Acumen Pharmaceuticals have?
Acumen Pharmaceuticals has 72,227,580 shares outstanding.
What happened to Acumen Pharmaceuticals’s price movement after its last earnings report?
Acumen Pharmaceuticals reported an EPS of -$0.4 in its last earnings report, beating expectations of -$0.453. Following the earnings report the stock price went down -3.042%.
Which hedge fund is a major shareholder of Acumen Pharmaceuticals?
Currently, no hedge funds are holding shares in ABOS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Acumen Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$8.00 (183.69% Upside)
$8.00 (183.69% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 4.8%
Last 30 Days ▼ 4.8%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-25.87%
12-Months-Change
Fundamentals
Return on Equity
-111.27%
Trailing 12-Months
Asset Growth
-48.54%
Trailing 12-Months
Company Description
Acumen Pharmaceuticals
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.
ABOS Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call conveyed strong scientific and preclinical progress (notably positive Phase Ib biomarkers for sabirnetug and robust EBD preclinical exposure gains of 14–40x), plus committed financing to advance the EBD program. At the same time, the company faces substantial ongoing R&D spend, a large 2025 net loss ($121.3M), and a relatively limited cash runway into early 2027, implying likely future financing needs and continued reliance on upcoming ALTITUDE-AD readout (late 2026) to de-risk the program. Overall, the positives around clinical momentum and preclinical differentiation are balanced by material financial and execution risks.View all ABOS earnings summariesABOS Stock 12 Month Forecast
Average Price Target
$8.00
▲(183.69% Upside)
Technical Analysis
Ownership Overview
32.37% Insiders
6.49% Mutual Funds
0.27% Other Institutional Investors
58.52% Public Companies and
Individual Investors